1,2,3,4-tetrahydroacridine-9-carboxylic acid (2-oxo-2-thiophen-2-ylethyl) ester is a **synthetic compound** that has been studied in the context of **anti-cancer research**.
Here's a breakdown:
**Structure:**
* **Tetrahydroacridine:** A core structure derived from acridine, a heterocyclic compound known for its biological activity.
* **9-carboxylic acid:** A carboxylic acid group attached to the 9th position of the tetrahydroacridine ring.
* **(2-oxo-2-thiophen-2-ylethyl) ester:** A specific ester group attached to the carboxylic acid. This group contains a thiophene ring, which is often found in compounds with pharmacological properties.
**Potential Importance in Research:**
* **Anti-Cancer Activity:** This compound has been shown to possess **anti-proliferative activity** against certain cancer cell lines. This means it can inhibit the growth and spread of cancer cells. The exact mechanism of its action is still under investigation, but it might involve targeting specific cellular pathways involved in cancer development.
* **Lead Compound for Drug Development:** The compound's anti-cancer activity makes it a potential lead compound for the development of new anti-cancer drugs. Further research is needed to optimize its pharmacological properties and assess its safety and efficacy in human studies.
**However, it's important to note:**
* **Limited Research:** The available information on this compound is limited. There is no definitive evidence yet to confirm its clinical relevance or potential benefits.
* **Pre-clinical Stage:** This compound is still at a pre-clinical stage of research, meaning it has not yet been tested in humans.
**In summary:** 1,2,3,4-tetrahydroacridine-9-carboxylic acid (2-oxo-2-thiophen-2-ylethyl) ester is a synthetic compound with potential anti-cancer activity. It is currently under investigation as a lead compound for drug development. However, more research is needed to fully understand its mechanism of action, efficacy, and safety.
| ID Source | ID |
|---|---|
| PubMed CID | 1077610 |
| CHEMBL ID | 1481086 |
| CHEBI ID | 109102 |
| Synonym |
|---|
| MLS000556174 , |
| smr000178254 |
| 1,2,3,4-tetrahydro-acridine-9-carboxylic acid 2-oxo-2-thiophen-2-yl-ethyl ester |
| OPREA1_014059 |
| OPREA1_086159 |
| AP-263/40971815 |
| 2-oxo-2-(2-thienyl)ethyl 1,2,3,4-tetrahydro-9-acridinecarboxylate |
| 2-oxo-2-(thiophen-2-yl)ethyl 1,2,3,4-tetrahydroacridine-9-carboxylate |
| STK327123 |
| CHEBI:109102 |
| AKOS000602664 |
| (2-oxo-2-thiophen-2-ylethyl) 1,2,3,4-tetrahydroacridine-9-carboxylate |
| HMS2480H24 |
| CHEMBL1481086 |
| 1,2,3,4-tetrahydroacridine-9-carboxylic acid (2-oxo-2-thiophen-2-ylethyl) ester |
| Q27188160 |
| Z19690673 |
| 380166-19-8 |
| Class | Description |
|---|---|
| acridines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 44.6684 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 22.3872 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 10.6910 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 100.0000 | 3.9811 | 27.7649 | 39.8107 | AID504842 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 27.5110 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 11.2202 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 10.0000 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 67.4555 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 44.6684 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 19.9526 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 12.5893 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 31.6228 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 31.6228 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| iron ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| calcium ion binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| protein binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| lipid binding | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 13S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 8(S)-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| arachidonate 15-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| linoleate 9S-lipoxygenase activity | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleus | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| cytosol | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| cytoskeleton | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| plasma membrane | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| adherens junction | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| focal adhesion | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| membrane | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| extracellular exosome | Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||